Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2011

ProteoTech, GSK Come Together for Parkinson Drug R&D

  • GlaxoSmithKline (GSK) has decided to help ProteoTech advance work in its alpha-synuclein therapeutic program. The companies aim to identify small molecules against misfolded proteins to treat Parkinson disease and other synucleinopathies.

    ProteoTech's lead small molecule, Synuclere™, targets alpha-synuclein aggregation and is currently in late preclinical stages of development. Initial support for this program was funded over a four-year period by the Michael J. Fox Foundation for Parkinson’s Research.

    ProteoTech is a private drug development company located in the Seattle, WA. Besides the Synuclere program, ProteoTech is developing Exebryl-1® for the treatment of diseases caused by beta-amyloid protein and tau protein aggregates and fibrils, like Alzheimer disease.

    Additionally, the firm is in early clinical studies with Systebryl™ for the treatment of systemic AA amyloidosis. ProteoTech is also in late preclinical development for a small peptide (Pepticlere™) for the treatment of Alzheimer disease beta-amyloid protein aggregates.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »